| ID Source | ID |
|---|---|
| PubMed CID | 16760569 |
| CHEMBL ID | 89768 |
| MeSH ID | M0164594 |
| Synonym |
|---|
| CHEMBL89768 , |
| mk571 |
| NCGC00163509-01 |
| sodium 3-[[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-[3-(dimethylamino)-3-oxopropyl]sulfanylmethyl]sulfanylpropanoate |
| mk-571.na |
| M02132 |
| tox21_112060 |
| mk-571 sodium |
| dtxcid3026358 |
| dtxsid5046358 , |
| cas-115103-85-0 |
| mk-571 sodium salt hydrate |
| S8126 |
| 115103-85-0 |
| AKOS022185251 |
| propanoic acid, 3-(((3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)-, sodium salt, (e)- |
| 4238L635XD , |
| unii-4238l635xd |
| mk-571 sodium salt |
| AC-32873 |
| HMS3649C10 |
| CS-5525 |
| mk-571 (sodium) |
| HY-19989A |
| J-003253 |
| mk-571 (sodium salt) |
| sodium (e)-3-(((3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoate |
| 1263184-04-8 |
| mk571 sodium salt |
| BCP17187 |
| verlukast sodium; mk-571 sodium |
| EX-A2327 |
| l-660711 sodium salt |
| l-660711 (sodium salt) |
| 3-[[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-[3-(dimethylamino)-3-oxopropyl]sulfanylmethyl]sulfanylpropanoate |
| CCG-269945 |
| propanoic acid, 3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-, sodium salt, (e)- (9ci) |
| Q27258482 |
| C71487 |
| A935155 |
| l-660771, sodium salt |
| sodium;3-[[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-[3-(dimethylamino)-3-oxopropyl]sulfanylmethyl]sulfanylpropanoate |
| AS-80024 |
| mk-571sodiumsalt |
| mk-571-d6sodiumsalt |
| propanoic acid, 3-[[[3-[(e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-, sodium salt (1:1) |
| (e)-3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-[[3-dimethylamino)-3-oxopropyl]thio]methyl]thio]-propanoic acid sodium salt |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 23.3222 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 9.7339 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743036; AID743042; AID743053; AID743054; AID743063 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 5.1924 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 8.9125 | 0.0054 | 28.0263 | 1,258.9301 | AID1346985 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 5.8361 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 3.7902 | 0.0010 | 19.4141 | 70.9645 | AID743094 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 4.4809 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 1.4960 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 0.1000 | 9.1916 | 31.6228 | AID1346983 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 27.6644 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 27.8028 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 5.5197 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 4.7308 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | IC50 (µMol) | 18.7850 | 0.0015 | 3.7110 | 9.6600 | AID1277331; AID365463 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 (µMol) | 20.7000 | 2.4100 | 6.3433 | 10.0000 | AID365464 |
| Cysteinyl leukotriene receptor 2 | Homo sapiens (human) | Ki | 0.0002 | 0.0002 | 0.9429 | 6.2000 | AID55237 |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | Ki | 0.0002 | 0.0002 | 1.5624 | 8.8720 | AID55237 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1277332 | Inhibition of ABCB1 in human KBV1 cells assessed as inhibition of calcein-AM efflux | 2016 | European journal of medicinal chemistry, Feb-15, Volume: 109 | Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization. |
| AID1277333 | Inhibition of ABCG2 in human MCF7/Topo cells by Hoechst 33342 assay | 2016 | European journal of medicinal chemistry, Feb-15, Volume: 109 | Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization. |
| AID88882 | Fold shift in LTD4 dose response curve following 280 mg intravenous dose in asthmatic patients. | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Modulators of leukotriene biosynthesis and receptor activation. |
| AID79848 | Compound was tested for LTD4 induced guinea pig trachea contraction | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Modulators of leukotriene biosynthesis and receptor activation. |
| AID1277331 | Inhibition of human MRP1 transfected in MDCK2 cells assessed as inhibition of calcein-AM efflux | 2016 | European journal of medicinal chemistry, Feb-15, Volume: 109 | Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization. |
| AID365463 | Inhibition of human MRP1 in human 2008 cells | 2008 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17 | A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins. |
| AID55237 | Binding affinity against Cysteinyl leukotriene D4 receptor | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Modulators of leukotriene biosynthesis and receptor activation. |
| AID365465 | Inhibition of P-gp in human A2780 cells | 2008 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17 | A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins. |
| AID365464 | Inhibition of human MRP2 expressed in dog MDCK2 cells | 2008 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17 | A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||